Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

Roche - Basel

Roche drug fails in lung cancer trial

Damages prospects for onartuzumab

- PMLiVE

NICE set to reject Lilly’s Alimta for new use in lung cancer

Drug deemed not cost-effective use of NHS resources in new indication

- PMLiVE

NICE relents and gives Pixuvri limited backing

Recommends Cell Therapeutics drug for an aggressive form of cancer

- PMLiVE

NICE backs new use for Bayer’s Eylea

Will go up against Novartis’ Lucentis in treatment of macular oedema in UK

National Institute for Health and Care Excellence NICE logo

Janssen launches diabetes drug Invokana in UK

Launch coincides with draft NICE recommendation for the SGLT2 inhibitor

Biogen Idec building

NICE turns down Biogen Idec’s oral MS drug

UK HTA body says Tecfidera is not a cost-effective use of NHS resources

- PMLiVE

NHS data project delayed in England

Public needs more time to learn about medical records database

National Institute for Health and Care Excellence NICE logo

NICE calls for greater statin prescribing in wake of Lipitor generics

Wants more use of the drugs to help prevent cardiovascular disease

National Institute for Health and Care Excellence NICE logo

NICE reviews lung cancer drug guidance

Consults on availability of Roche's Tarceva and AZ's Iressa on NHS

- PMLiVE

Novo partners with NHS on diabetes care

Danish pharma company will work with King’s Health Partners in South London

- PMLiVE

NICE backs Astellas’ Xtandi in prostate cancer

But company criticises restrictions imposed by HTA body for England

- PMLiVE

NICE set to extend MabThera recommendation

Says Roche’s drug can be used on NHS to treat two serious forms of vasculitis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links